Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases
01 mai 2019 07h30 HE
|
Biogen Inc.
Data demonstrate that pre-symptomatic infants with SMA treated with SPINRAZA® (nusinersen) over three years achieved motor milestones that are more consistent with normal childhood...
La réaction de Biogen aux recommandations mises à jour de l’ACMTS concernant l’accès à SPINRAZA
01 mars 2019 20h18 HE
|
Biogen Canada
·L’Agence canadienne des médicaments et des technologies de la santé (ACMTS) a élargi ses recommandations concernant le financement par les fonds publics du traitement des patients atteints...
Biogen Responds to CADTH’s updated recommendation regarding coverage for SPINRAZA
01 mars 2019 20h18 HE
|
Biogen Canada
·Canadian Association of Drugs and Technologies in Health (CADTH) has expanded their recommendations for public reimbursement for SMA patients ·The recommendation, however, continues to limit access...
Biogen salue la décision du Québec de rembourser SPINRAZAMC (nusinersen) pour une vaste population de patients atteints d’amyotrophie spinale (AS)
20 déc. 2018 12h19 HE
|
Biogen Canada
MISSISSAUGA, Ontario, 20 déc. 2018 (GLOBE NEWSWIRE) -- Cette décision découle de la recommandation positive de l’Institut national d’excellence en santé et services sociaux (INESSS) qui...
Biogen Applauds Quebec Decision to Cover SPINRAZA™ (nusinersen) for a broad population of SMA Patients
20 déc. 2018 12h19 HE
|
Biogen Canada
The decision follows positive recommendation from the Institut national d'excellence en santé et services sociaux (INESSS) recognising the urgency and need for a treatment for patients with SMA and...
International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product
29 nov. 2018 07h30 HE
|
Biogen Inc.
CAMBRIDGE, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has been awarded the 2018 International Prix Galien as Best Biotechnology Product for SPINRAZA (nusinersen), the first...